WTZ Cancer Center Director Univ. Prof. Dr. med. Angelika Eggert ...

2. Coordinator:
Prof. Dr. med. Martin Stuschke,
Director, Dept. of Radiotherapy
6. Selected publications
Pöttgen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, Stamatis G, Wagner H,
Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M.
Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with
neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial.
J Clin Oncol. 2007;25:4987-92. IF 13,6
Sak A, Fegers I, Groneberg M and Stuschke M. The effect of separase depletion on ionising
radiation induced cell-cycle checkpoints and survival in human lung cancer cell lines.
Cell Prolif. 2008, in press. IF 4.5
Eberhardt W, Pöttgen C, Stuschke M. Chemoradiation paradigm for the treatment of lung cancer.
Nat Clin Pract Oncol. 2006;3:188-99. New
Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G,
Gauler T, Antoch G, Bockisch A, Stuschke M. Value of 18F-fluoro-2-deoxy-D-glucose-positron
emission tomography/computed tomography in non-small-cell lung cancer for prediction of
pathologic response and times to relapse after neoadjuvant chemoradiotherapy.
Clin Cancer Res. 2006;12:97-106 IF 5.6
Sak A, Stueben G, Groneberg M, Bocker W, Stuschke M. Targeting of Rad51-dependent
homologous recombination: implications for the radiation sensitivity of human lung cancer
cell lines.
Br J Cancer. 2005; 28:1089-97. IF 3.7
Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W,
Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery
in patients with locally advanced squamous cell carcinoma of the esophagus.
J Clin Oncol. 2005;23:2310-7. IF 9.8
Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I,
Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD.
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more
effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally
advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group
of the German Cancer Society 95-06 Prospective Randomized Trial.
J Clin Oncol. 2005;23:1125-35. IF 9.8
Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M, Thews O, Vaupel P.
Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human
tumors in nude mice.
Int J Radiat Oncol Biol Phys. 2003; 55:1358-62. IF 4.3
Marnitz S, Stuschke M, Bohsung J, Moys A, Reng I, Wurm R, Budach V. Intraindividual
comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy
in the therapy of locally advanced non-small cell lung cancer a planning study.
Strahlenther Onkol 2002;178: 651-8. IF 3.1
Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S. Update
on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental
predispositions, clinical manifestations, and therapy.
Lancet Infect Dis 2002; 2: 281-92. IF 10.8
Sak A, Stuschke M, Wurm R, Schroeder G, Sinn B, Wolf G, Budach V. Selective inactivation of
DNAdependent protein kinase with antisense oligodeoxynucleotides: consequences for the
rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer
cell lines.
Cancer Res 2002; 62: 6621-4. IF 8.4
Stuschke M, Sak A, Wurm R, Sinn B, Wolf G, Stuben G, Budach V. Radiation-induced apoptosis in
human non-small-cell lung cancer cell lines is secondary to cell-cycle progression beyond
the G2-phase checkpoint.